Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NYC ephedra bill

This article was originally published in The Tan Sheet

Executive Summary

Persons selling herbal ephedra products could be subject to criminal fines of up to $1,000 in addition to civil fines of up to $1,000 under legislation introduced in New York City Council April 30 by minority leader James Oddo (R-Staten Island) and others. Ban would exempt FDA-approved OTCs, certified alternative medical practitioners, although it would not allow practitioners to prescribe botanical for weight loss, energy/athletic performance. Bill was referred to Health Committee. Similar measure banning ephedra was introduced in state assembly March 12 and referred to Codes Committee April 1 (1"The Tan Sheet" April 14, 2003, In Brief)...

You may also be interested in...

New York ephedra bill

Legislation to "ban the sale of supplements that contain ephedra in New York State except for the drugs under FDA supervision" recently introduced in state assembly. FDA's recent warning label proposal "fails to adequately address the risks" of ephedra, assemblywoman Audrey Pheffer says in March 19 comments to FDA urging national ban of the botanical. Bill A 6921, introduced March 12, would institute fines "of not more than $500 per violation" and statewide ban would apply to synthetic and natural forms sold as "Sea Grape, Yellow Horse, Country Mallow...Teamster's Tea and Yellow Astringent," among others, legislation states...

Stalemate Over Virtual Audits In EU As Commission Tells TEAM-NB To Back Off

Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.

Amneal’s Generics Business Reinvigorated By New Launches

As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts